Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ardizzone

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Joint Bone Spine|May 1, 2022
Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritidesRenaud Felten, Marion Geoffroy, Loïs Bolko, et al.
Annals of the Rheumatic Diseases|September 24, 2021
B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologicsRenaud Felten, Pierre-Marie Duret, Elodie Bauer, et al.
Annals of the Rheumatic Diseases|July 12, 2022
Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016-2017Pauline Richebé, Guillaume Coiffier, Pascal Guggenbuhl, et al.
JAMA|September 23, 2016
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical TrialJacques-Eric Gottenberg, Olivier Brocq, Aleth Perdriger, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Joint Bone Spine|May 1, 2022
Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritidesRenaud Felten, Marion Geoffroy, Loïs Bolko, et al.
Annals of the Rheumatic Diseases|September 24, 2021
B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologicsRenaud Felten, Pierre-Marie Duret, Elodie Bauer, et al.
Annals of the Rheumatic Diseases|July 12, 2022
Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016-2017Pauline Richebé, Guillaume Coiffier, Pascal Guggenbuhl, et al.
JAMA|September 23, 2016
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical TrialJacques-Eric Gottenberg, Olivier Brocq, Aleth Perdriger, et al.
Pageof 2